公开(公告)号：US20190248897A1

公开(公告)日：2019-08-15

申请号：US16256824

申请日：2019-01-24

Applicant: Zymeworks Inc.

Inventor： Gordon Yiu Kon Ng ,  Surjit Bhimarao Dixit ,  Thomas Spreter von Kruedenstein ,  Nina E. Weisser

IPC: C07K16/28 ,  C07K16/32

CPC classification number: C07K16/2809 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/74 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31

Abstract: Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3.

公开(公告)号：US20180186862A1

公开(公告)日：2018-07-05

申请号：US15900211

申请日：2018-02-20

Applicant: University of Maryland, Baltimore ,  Gliknik Inc.

Inventor： Scott E. STROME ,  Dan H. SCHULZE ,  David S. BLOCK ,  Henrik OLSEN

IPC: C07K16/00 ,  C07K16/32 ,  G01N33/50 ,  C07K16/06 ,  C07K16/18 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/57 ,  C07K16/065 ,  C07K16/18 ,  C07K16/28 ,  C07K16/283 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/50 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2318/00 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/5047 ,  G01N2500/10 ,  Y02A50/412

Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases

公开(公告)号：US09926362B2

公开(公告)日：2018-03-27

申请号：US15483873

申请日：2017-04-10

Applicant: University of Maryland, Baltimore ,  Gliknik Inc.

Inventor： Scott E. Strome ,  Dan H. Schulze ,  David S. Block ,  Henrik Olsen

IPC: A61K39/00 ,  C07K16/00 ,  C07K16/18 ,  C07K16/28 ,  C07K16/32 ,  C07K16/06 ,  G01N33/50

CPC classification number: C07K16/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/57 ,  C07K16/065 ,  C07K16/18 ,  C07K16/28 ,  C07K16/283 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/50 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2318/00 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/5047 ,  G01N2500/10 ,  Y02A50/412

Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.

公开(公告)号：US20180057604A1

公开(公告)日：2018-03-01

申请号：US15525821

申请日：2015-11-18

Applicant: Genentech, Inc. ,  Adimab LLC

Inventor： Yichin Liu ,  Jasvinder Atwal ,  Cecilia Pui Chi Chiu ,  Ryan J. Watts ,  Yan WU ,  Eric Krauland ,  Michael Feldhaus ,  Yin Zhang ,  Joy Yu Zuchero ,  Jessica Couch ,  Mark S Dennis ,  James A Ernst ,  Gregory A Lazar

IPC: C07K16/40 ,  C07K16/28 ,  G01N33/68

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K16/22 ,  C07K16/2881 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/00 ,  C12Y304/23046 ,  G01N33/6896 ,  G01N2333/70582 ,  G01N2333/96472 ,  G01N2800/28 ,  G01N2800/52

Abstract: The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.

公开(公告)号：US09862769B2

公开(公告)日：2018-01-09

申请号：US13700341

申请日：2011-05-27

Applicant: Bart De Goeij ,  Simone De Haij ,  Thilo Riedl ,  Rene Hoet ,  Ole Baadsgaard ,  Jan Van De Winkel ,  David Satijn ,  Paul Parren ,  Aran Frank Labrijn ,  Joyce Meesters ,  Janine Schuurman ,  Edward N. Van Den Brink

Inventor： Bart De Goeij ,  Simone De Haij ,  Thilo Riedl ,  Rene Hoet ,  Ole Baadsgaard ,  Jan Van De Winkel ,  David Satijn ,  Paul Parren ,  Aran Frank Labrijn ,  Joyce Meesters ,  Janine Schuurman ,  Edward N. Van Den Brink

IPC: A61K39/395 ,  C07K16/00 ,  C07K16/28 ,  C07K16/32 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/92

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related anti-body-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US09856327B2

公开(公告)日：2018-01-02

申请号：US15186167

申请日：2016-06-17

Applicant: Xencor, Inc.

Inventor： Matthew J. Bernett ,  Gregory Moore ,  John Desjarlais ,  Seung Chu ,  Rumana Rashid ,  Umesh Muchhal ,  Sung-Hyung Lee

IPC: C07K16/00 ,  C07K16/46 ,  C07K16/28 ,  C07K16/30 ,  C07K16/40 ,  A61K39/00

CPC classification number: C07K16/468 ,  A61K2039/505 ,  C07K16/2809 ,  C07K16/2866 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/3061 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/70 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention is directed to novel heterodimeric antibodies.

公开(公告)号：US20170218049A1

公开(公告)日：2017-08-03

申请号：US15483873

申请日：2017-04-10

Applicant: University of Maryland, Baltimore ,  Gliknik Inc.

Inventor： Scott E. STROME ,  Dan H. SCHULZE ,  David S. BLOCK ,  Henrik OLSEN

IPC: C07K16/00 ,  G01N33/50

CPC classification number: C07K16/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/57 ,  C07K16/065 ,  C07K16/18 ,  C07K16/28 ,  C07K16/283 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/50 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2318/00 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/5047 ,  G01N2500/10 ,  Y02A50/412

Abstract: IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacement compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases

公开(公告)号：US09650446B2

公开(公告)日：2017-05-16

申请号：US14205248

申请日：2014-03-11

Applicant: Xencor, Inc.

Inventor： Gregory Moore ,  Matthew Bernett ,  Rumana Rashid ,  John Desjarlais

IPC: C07K16/00 ,  C07K16/46 ,  C07K16/28

CPC classification number: C07K16/468 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/528 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/64 ,  C07K2317/94

Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.

公开(公告)号：US20170088603A1

公开(公告)日：2017-03-30

申请号：US15123038

申请日：2015-03-05

Applicant: UCB BIOPHARMA SPRL

Inventor： Farnaz FALLAH-ARANI ,  Robert Anthony GRIFFIN ,  David Paul HUMPHREYS ,  Shirley Jane PETERS ,  Bryan John SMITH ,  Paul Edward STEPHENS

IPC: C07K16/00 ,  C12P21/02 ,  C12N15/62

CPC classification number: C07K16/00 ,  A61K2039/505 ,  C07K16/46 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/53 ,  C07K2317/62 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/62 ,  C12P21/02

Abstract: The invention relates to multimeric fusion proteins which bind to human Fc receptors. The invention also relates to therapeutic compositions comprising the proteins, and their use in the treatment of immune disorders.

公开(公告)号：US20140356381A1

公开(公告)日：2014-12-04

申请号：US14214418

申请日：2014-03-14

Applicant: Xencor, Inc.

Inventor： Gregory Moore ,  Matthew Bernett ,  John Desjarlais

IPC: C07K19/00

CPC classification number: C07K19/00 ,  C07K16/00 ,  C07K16/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/94 ,  C07K2319/00

Abstract: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as antigen-1 and antigen-2 respectively (or antigen-3 and antigen-4, if applicable. As outlined herein, a number of different formats can be used, with some scaffolds relying combinations of monovalent and bivalent bindings.

Abstract translation: 本发明描述了共同接合至少两种抗原的新型免疫球蛋白组合物，例如， 如本文所概述的，第一和第二抗原或三种或四种抗原可以以本文所述的一些支架形式结合。 本发明的第一和第二抗原在本文中分别称为抗原-1和抗原-2（或抗原-3和抗原-4）（如果适用）。如本文所述，可以使用多种不同的形式，一些支架依赖 一价和二价结合的组合。